Abstract
Purpose
A 31-year-old woman suffered a 4th relapse of epithelial ovarian cancer refractory to several cytotoxic drugs including platinum, paclitaxel, and topotecan.
Methods
Sequential high-dose chemotherapy with autografting (three courses) led to a minor response of short duration. In order to induce a graft-versus-tumor effect, allogeneic hematopoietic stem cell transplantation (HSCT) from an HLA-identical sibling donor, after dose-reduced conditioning, was performed in January 2001.
Results
On day +51 the patient developed acute grade II graft-versus-host disease of the skin and gastrointestinal tract, which was successfully treated by prednisolone. Six months after allogeneic HSCT a complete disappearance of the tumor could be seen. Unfortunately, 14 months later a 5th relapse was diagnosed.
Conclusions
This case demonstrates, on the one hand, that allogeneic HSCT is able to induce complete remissions (CR) in chemoresistant ovarian cancer. On the other hand, despite achievement of CR after allografting, the chance of cure remains limited for these patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bay JO, Fleury J, Choufi B, Tournilhac O, Vincent C, Bailly C, Dauplat J, Viens P, Faucher C, Blaise D (2002) Allogeneic hematopoietic stem cell transplantation in ovarian cancer: results of five patients. Bone Marrow Transplant 30:95–102
Bertucci F, Viens P, Delpero JR, Bardou VJ, Faucher C, Houvenaeghel G, Maraninchi D (2000) High-dose melphalan-based chemotherapy and autologous stem cell transplantation after second-look laparotomy in patients with chemosensitive advanced ovarian cancer: long-term results. Bone Marrow Transplant 26:61–67
Bojko P, Scheulen ME, Hilger R, Oberhoff C, Schindler AE, Seeber S (2001) High-dose chemotherapy with peripheral blood stem cell transplantation for patients with advanced ovarian cancer. J Cancer Res Clin Oncol 127:243–250
Childs R, Chernoff A, Contentin N, Bahceci E, Shrump D, Leitman S, Read EJ, Tisdale J, Dunbar C, Linehan WM, Young NS, Barrett AJ (2000) Regression of metastatic renal-cell carcinoma after non-myeloablative allogeneic peripheral blood stem cell transplantation. N Engl J Med 343: 750–758
Eibl B, Schwaighofer H, Nachbaur D, Marth C, Gachter A, Knapp R, Bock G, Gassner C, Schiller L, Petersen F, Niederwieser D (1996) Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer. Blood 88:1501–1508
Gratwohl A, Passweg J, Baldomero H, Urbano-Ispizua A for the European Group of Blood and Marrow Transplantation (EBMT) (2001) Hematopoietic stem cell transplantation activity in Europe 1999. Bone Marrow Transplant 27:899–916
Hogberg T, Glimelius B, Nygren P for the SBU-group (2001) A systemic overview of chemotherapy effects in ovarian cancer. Acta Oncol 40:340–360
Holmberg LA, Demirer T, Rowley S, Buckner CD, Goodman G, Maziarz R, Klarnet J, Zuckerman N, Harrer G, McCloskey R, Gersh R, Goldberg R, Nichols W, Jacobs A, Weiden P, Montgomery P, Rivkin S, Appelbaum FR, Bensinger WI (1998) High-dose busulfan, melphalan and thiotepa followed by autologous peripheral blood stem cells (PBSC) rescue in patients with advanced stage III/IV ovarian cancer. Bone Marrow Transplant 22:651–659
Jones RJ, Ambinder RF, Piantadosi S, Santos GW (1991) Evidence of graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649–653
Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D (1995) Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86:2041–2050
Legros M, Dauplat H, Fleury J, Cure H, Suzanne F, Chassagne J, Bay JO, Sol C, Canis M, Condat P, Choufi B, Tavernier F, Glenat C, Chollet P, Plagne R (1997) High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results. J Clin Oncol 15:1302–1308
Morgan RJ, Doroshow JH, Leong L, Schriber J, Shibata S, Forman S, Hamasaki V, Margolin K, Somlo G, Alvarnas J, McNamara M, Longmate J, Raschko J, Chow W, Vasilev S, McGonigle K, Yen Y (2001) Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer. Bone Marrow Transplant 28:859–863
Peethambaram PP, Long HJ (2002) Second-line and subsequent therapy for ovarian carcinoma. Curr Oncol Rep 4:159–164
Platzbecker U, Bandt D, Thiede C, Helwig A, Freiberg-Richter J, Schuler U, Plettig R, Geissler G, Rethwilm A, Ehninger G, Bornhauser M (2001) Successful preemptive cidofovir for CMV antigenemia after dose-reduced conditioning and allogeneic blood stem cell transplantation. Transplantation 71:880–885
Rosti G, Ferrante P, Ledermann J, Levyraz S, Ladenstein R, Koscileniak E, Crown J, Dazzi C, Cariello A, Marangolo M (2002) High-dose chemotherapy for solid tumors: results of the EBMT. Crit Rev Oncol Hematol 41:129–140
Salerno MG, Ferrandina G, Greggi S, Pierelli L, Menichella G, Leone G, Scambia G, Manusco S (2001) High-dose chemotherapy as a consolidation approach in advanced ovarian cancer: long-term results. Bone Marrow Transplant 27:1017–1025
Shinozuka T, Muramatsu T, Miyamoto T, Hirasawa T, Murakami M, Makino T, Sadahiro S, Tanaka Y, Yasuda M (1999) Long-term results and prognostic analysis in advanced and recurrent/refractory epithelial ovarian cancer treated by high-dose cyclophosphamide, adriamycin, and cisplatin with autologous bone marrow transplantation. Int J Clin Oncol 4:273–279
Stiff PJ, Veum-Stone J, Lazarus HM, Ayash L, Edwards JR, Keating A, Klein JP, Oblon DJ, Shea TC, Thome S, Horowitz MM (2000) High-dose chemotherapy and autologous stem-cell transplantation for ovarian cancer: an Autologous Blood and Marrow Transplant Registry report. Ann Intern Med 133:504–515
Thiede C, Florek M, Bornhauser M, Ritter M, Mohr B, Brendel C, Ehninger G, Neubauer A (1999) Rapid quantification of mixed chimerism using multiplex amplification of short tandem repeat markers and fluorescence detection. Bone Marrow Transplant 23:1055–1060
Ueno NT, Rondon G, Mirza NQ, Geisler DK, Anderlini P, Giralt SA, Andersson BS, Claxton DF, Gajewski JL, Khouri IF, Korbling M, Mehra RC, Przepiorka D, Rahman Z, Samuels BI, van Besien K, Hortobagy GN, Champlin RE (1998) Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer. J Clin Oncol 16:986–993
Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ (1996) Graft-versus-myeloma effect in two cases. Lancet 347:800–801
Wandt H, Birkmann J, Denzel T, Schäfer K, Schwab G, Pilz D, Egger H, Both A, Gallmeier WM (1999) Sequential cycles of high-dose chemotherapy with dose escalation of carboplatin with or without paclitaxel supported by G-CSF mobilized peripheral blood progenitor cells: a phase I/II study in advanced ovarian cancer. Bone Marrow Transplant 23:763–770
Weiden PL, Flournoy N, Thomas ED, Prentice R, Fefer A, Buckner CD, Storb R (1979) Antileukemic effects of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N Engl J Med 300:1068–1073
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hänel, M., Bornhäuser, M., Müller, J. et al. Evidence for a graft-versus-tumor effect in refractory ovarian cancer. J Cancer Res Clin Oncol 129, 12–16 (2003). https://doi.org/10.1007/s00432-002-0399-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-002-0399-1